Atara Biotherapeutics recently published an update of the company’s quarterly financial results and operational highlights, including the advancement of its T-cell based immunotherapy strategies for multiple sclerosis (MS) and cancer. One of the investigational therapies featured in the report is ATA188, a potential treatment for MS.
Epstein-Barr virus
(Editor’s note: Tamara Sellman continues her occasional series on the MS alphabet with this second of two parts on terms starting with the letter “E.” Read the first part here.) When it comes to multiple sclerosis, mastering an understanding of the disease means you…
An investigational treatment called ATA188 that wipes out B-cells targeting the Epstein-Barr virus (EBV) has shown promise as a multiple sclerosis treatment, a Phase 1 clinical trial involving a small patient group indicates. The trial, conducted in Australia, covered six people with primary or secondary progressive MS. B-cells are a…
Multiple sclerosis (MS) is thought to be caused by genetic factors, but environmental cues are increasingly recognized to have an impact on disease onset and development. One environmental factor suggested to play a role in MS is infectious agents, such as viruses. Now, different teams of scientists have explored the…
Researchers investigating immune B-cell response to the Epstein-Barr virus (EBV) and cytomegalovirus (CMV) found that it may correlate with the amount of brain-specific B-cells in the blood — a marker of multiple sclerosis (MS) — and with higher disease activity. The findings were published in the journal Viruses, in…
A systematic review of existing medical literature on multiple sclerosis (MS) could shed light on MS causes and predictors for disease progression, and on lifestyle changes — ranging from vitamin D intake to weight loss — that might reduce a person’s risk. The report, “Factors associated with onset, relapses…